Article

Pharmaceutical Company to Pay $95M to Settle Allegations of Improper Drug Promotion

Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.

The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis.

Read the full story: http://wapo.st/R32A1a

Source: The Washington Post

Related Videos
Molly Dean, MSW, Siftwell
Molly Dean, MSW, Siftwell
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Dr Andrew S. Oseran
o Richard Hughes IV, JD, MPH, Epstein Becker Green
Dr Andrew S. Oseran
Dr Andrew S. Oseran
Dr Maria DeYoreo
Dr Maria DeYoreo
Related Content
Medical data-everythingpossible-stock.adobe.com
March 13th 2025

As Claims Denials Surge, AI and Data-Driven Insights Equip Clinicians, Hospitals to Fight Back

Giuliana Grossi Pearl Steinzor
As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in shaping the future of patient care, according to experts from Komodo Health and SmarterDx.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Person pushing button with slight frowning face | Image credit: EDER – stock.adobe.com
March 11th 2025

Americans Give US Health Care System a C Grade, Calling for Policy Change

Hayden E. Klein
A new report shows most Americans believe the government is too involved in health care regulation and want to see a ban on pharmaceutical company advertisements in the US.
Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care
February 11th 2025

Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care

Maggie L. Shaw George Jones
George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.
Dermatology illustration | Image Credit: ibreakstock - stock.adobe.com
March 7th 2025

Shaping Dermatology's Future by Increasing Access, Data, and Advocacy

Brooke McCormick
Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
The report estimates that the loss of enhanced PTCs would lead to a $26.1 billion reduction in federal tax credits given to individuals, health insurers, and in turn, health care providers. | Image credit: onephoto - stock.adobe.com
March 6th 2025

Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates

Rose McNulty
Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo